Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to
rapidly improve symptoms in depression. Even a single dose of ketamine has been shown to
improve depression and cognition with short-term memory, inhibitory control, cogniti...
Age: 50 - 90 years
Gender: All
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of
settings within health care systems, for remote settings, and in community settings where it
can be integrated into COVID-19 programs and subsequent treatment plans.
Thi...
Age: 18 years - 66+
Gender: All
Mitigation of Postoperative Delirium in High-Risk Patients
Among patients with cognitive impairment (CI) that undergo surgery, the risk for developing
postoperative delirium (POD) is high (50%) and associated with further morbidity and
mortality. Yet, 30-40% of POD cases are preventable with perioperative management. This
...
Age: 18 - 120 years
Gender: All
Alzheimer's Disease Neuroimaging Initiative 4
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical
trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies...
Age: 55 - 90 years
Gender: All
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
The purpose of this research study is to investigate the effect of a light treatment on
sleep, memory and brain function. In people with mild cognitive impairment (MCI) and
Alzheimer's disease, sleep-wake disturbance is evident in up to 60% of patients. This can be
...
Age: 50 - 85 years
Gender: All
Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment
This pilot randomized controlled trial is to investigate the feasibility and efficacy of
cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally,
the study will obtain preliminary data, using rsfMRI, regarding the potential underl...
Age: 18 years - 66+
Gender: All
Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
Participants will randomly be placed into one of four groups and experience one of the four
following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic
light [RL]); (2) a placebo light with a random flicker (placebo condition for rhythm...
Age: 55 years - 66+
Gender: All
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep
and cognition in a controlled laboratory study. A lab study will allow the collection of
electroencephalogram (EEG) data, perform cognitive tests, and observe the response ...
Age: 55 years - 66+
Gender: All
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
This study compares different music therapy (MT) experiences and their impact on memory and
language in patients with Alzheimer's disease and Mild Cognitive Impairment.
The 12-month study will assess the role of common experiences involving familiar music and
ot...
Age: 55 years - 66+
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
To test the long term effect of a light treatment on cognition, sleep and metabolism in
patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia
(ADRD).
Age: 55 years - 66+
Gender: All
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
...
Age: 55 - 90 years
Gender: All